Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C13H15Cl2N3O2S
CAS Number:
Molecular Weight:
348.25
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Product Name
GLP-1R agonist, ≥98% (HPLC)
SMILES string
[S](=O)(=O)(C)c1nc2c(nc1NC(C)(C)C)cc(c(c2)Cl)Cl
InChI
1S/C13H15Cl2N3O2S/c1-13(2,3)18-11-12(21(4,19)20)17-10-6-8(15)7(14)5-9(10)16-11/h5-6H,1-4H3,(H,16,18)
InChI key
GNZCSGYHILBXLL-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
light brown-yellow
solubility
DMSO: ≥10 mg/mL
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
GLP-1R is a small molecule GLP-1 receptor agonist.
GLP-1R is a small molecule GLP-1 receptor agonist. GLP-1 receptor signaling is a predominant mechanism for regulating glucose homeostasis. This compound represents a unique non-peptide tool for studying the role of GLP-1 in both in vivo and in vitro diabetes and obesity models.
General description
Glucagon-like peptide-1 receptor (GLP-1R) agonist is a potential oral drug for modulating glucagon-like peptide (GLP)-1 in diabetic patients. GLP-1R agonists play a key role in lowering glycated hemoglobin levels. It improves glycemic control and maintenance of body weight.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
Garber AJ.
Diabetes Care, 34(Supplement 2), S279-S284 (2011)
GLP-1 receptor agonists: a review of head-to-head clinical studies.
Trujillo JM, et al.
Therapeutic advances in endocrinology and metabolism, 6(1), 19-28 (2015)
Small-molecule agonists for the glucagon-like peptide 1 receptor.
Knudsen LB, et al.
Proceedings of the National Academy of Sciences of the USA, 104(3), 937-942 (2007)
Juliana de F Germano et al.
Scientific reports, 10(1), 8284-8284 (2020-05-20)
Given that adverse remodeling is the leading cause of heart failure and death in the USA, there is an urgent unmet need to develop new methods in dealing with this devastating disease. Here we evaluated the efficacy of a short-course
Juliana de Freitas Germano et al.
International journal of molecular sciences, 22(16) (2021-08-28)
Cardiovascular disease is the main cause of death worldwide, making it crucial to search for new therapies to mitigate major adverse cardiac events (MACEs) after a cardiac ischemic episode. Drugs in the class of the glucagon-like peptide-1 receptor agonists (GLP1Ra)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service